References
- Steinberg WM, Gelfand R, Anderson KK, Glenn J, Kurtzman SH, Sindelar WF, et al. Comparison of the sensitivity and specificity of the CA19-9 and carcinoembryonic antigen assays in detecting cancer of the pancreas. Gastroenterology. 1986;90(2):343–9.
- Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol. 1990;85(4):350–5.
- Goede E, Yap S. An exceptional high concentration of serum CA 19.9 in a patient with alcoholic liver disease. Gut. 1997;41(4):577–578.
- Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, et al. International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31(5):929–38.10.1016/S0168-8278(99)80297-9
- Farini R, Fabris C, Bonvicini P, Piccoli A, Del Favero G, Venturini R, et al. CA 19-9 in the differential diagnosis between pancreatic cancer and chronic pancreatitis. Eur J Cancer Clin Oncol. 1985;21(4):429–32.10.1016/0277-5379(85)90032-X
- Siqueira E, Schoen R, Silverman W, Martin, J, Rabinovitz, M, Weissfield, JL, Abu-Elmaagd, K, Madariaga, JR, Slivka, A. Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. Gastrointest Endosc. 2002;56:40–7.10.1067/mge.2002.125105
- Kim H, Lee K, Kim SH, Lee, JK, Lim, JH, Paik, SW, Rhee, JC. Differential diagnosis of intrahepatic bile duct dilatation without demonstrable mass on ultrasonography or CT: benign versus malignancy. J Gastroenterol Hepatol. 2003;18:1287–92.10.1046/j.1440-1746.2003.03169.x
- Bertino G, Ardiri A, Malaguarnera M, Malaguarnera G, Bertino N, Calvagno GS. Hepatocellualar carcinoma serum markers. Semin Oncol. 2012;39(4):410–33. doi:10.1053/j.seminoncol.2012.05.001. Review.
- Andriulli A, Gindro T, Piantino P, Farini R, Cavallini G, Piazzi L, et al. Prospective evaluation of the diagnostic efficacy of CA 19-9 assay as a marker for gastrointestinal cancers. Digestion. 1986;33(1):26–33.10.1159/000199271
- Maestranzi S, Przemioslo R, Mitchell H, Sherwood, R.A. The effect of benign and malignant liver disease on the tumour markers CA 19-9 and CEA. Ann Clin Biochem. 1998;35:99–103.10.1177/000456329803500113
- Takahashi Y, Takeuchi T, Sakamoto J, Touge T, Mai M, Ohkura H, et al. The usefulness of CEA and/or CA19-9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study. Gastric Cancer. 2003;6:142–5.10.1007/s10120-003-0240-9
- Calisto JL, Tagle M, Bedoya P, Scavino Y, Luna E, Poletti L, et al. Autoimmune hepatitis with elevation of CA 19-9 and normalization with immunosuppressant [corrected]treatment: case report and review of the literature. Rev Gastroenterol Peru. 2008;28(2):167–70.
- Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, et al. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51(6):2193–213. doi:10.1002/hep.23584.